美国 · 股市与财经 · Morningstar

Vivacta Bio and Grit Bio Announce FDA Orphan Drug Designation for In Vivo CAR-T Therapy GT801 in Autoimmune Hemolytic Anemia

来源：Morningstar · 美国 19 小时前

SHANGHAI, Oct. 17, 2026 /PRNewswire/ -- Vivacta Biotechnology (Shanghai) Co., Ltd. ("Vivacta Bio"), a company spun out of the in vivo CAR-T platform of Beijing Grit…

在 Morningstar 阅读全文登录后可收藏

MediaNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.morningstar.com)

Vivacta Bio and Grit Bio Announce FDA Orphan Drug Designation for In Vivo CAR-T Therapy GT801 in Autoimmune Hemolytic Anemia

推荐阅读

AI stocks plunge. Inflation heats up. Where we're still finding opportunities

Earnings Scoreboard: 83% of S&P 500 early reporters beat EPS estimates as Y/Y profit growth hits 23 firms

I'm a Colorado local. If I had one day to show you my state, I'd skip Denver and take you to a city just west of it.

Ember’s new temperature-controlled mug makes my nightly tea ritual even better

The Reporter Who Exposed Elizabeth Holmes on Nathan Fielder’s Documentary

The odd history behind candy corn and your favorite Halloween candy

Vivacta Bio and Grit Bio Announce FDA Orphan Drug Designation for In Vivo CAR-T Therapy GT801 in Autoimmune Hemolytic Anemia

分享

推荐阅读

AI stocks plunge. Inflation heats up. Where we're still finding opportunities

Earnings Scoreboard: 83% of S&P 500 early reporters beat EPS estimates as Y/Y profit growth hits 23 firms

I'm a Colorado local. If I had one day to show you my state, I'd skip Denver and take you to a city just west of it.

Ember’s new temperature-controlled mug makes my nightly tea ritual even better

The Reporter Who Exposed Elizabeth Holmes on Nathan Fielder’s Documentary

The odd history behind candy corn and your favorite Halloween candy